Openbookopenbook
Equity
StockUS listing USALTNASDAQHealthcareEarnings Deterioration

Altimmune Inc(ALT) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk29Low
75%Data
Revenue growing 420% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 532.01M
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ29 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ALT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Altimmune Inc?

, a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.

AI Brief Pro

The brief on Altimmune Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Altimmune Inc?

, a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 532.01M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

CBIOSmall Cap / 532M market cap
Crescent Biopharma, Inc.
Compare
OCSSmall Cap / 538M market cap
Oculis Holding AG Ordinary shares
Compare
PRMESmall Cap / 541M market cap
Prime Medicine, Inc. Common Stock
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap532.01M
P/E RatioN/A
Dividend YieldN/A
Beta0.176
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
330,000 shares
$109k
9-12months
0
325,527 shares
$105k
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.